Savient ($SVNT) is grappling with a high-profile lawsuit from the hedge fund Tang Capital, which accuses the company of bungling the launch of its gout drug Krystexxa--and contends that Savient is essentially insolvent. Report
Savient ($SVNT) is grappling with a high-profile lawsuit from the hedge fund Tang Capital, which accuses the company of bungling the launch of its gout drug Krystexxa--and contends that Savient is essentially insolvent. Report